

LONZA GROUP AG

ISIN: CH0013841017 WKN: 1384101 Asset Class: **Stock**

Company

2024/05/10 17:31:10

LONZA

Price

526.20

CHF

Difference

-0.04% (-0.20)



Contact Details

LONZA GROUP AG

Tel: +41-61-316-81-11

--

Fax: +41-61-316-91-11

Muenchensteinerstrasse 38

Web: <http://www.lonza.com>

4002 Basel

E-mail: media@lonza.com

Company Profile

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	4,885,000,000		5,712,000,000		5,933,000,000	
Common stock capital		74,000,000		74,000,000		74,000,000
Fixed assets	12,198,000,000		11,845,000,000		10,758,000,000	
Equity capital of a company		9,512,000,000		10,665,000,000		9,823,000,000
Cash and cash equivalents	1,468,000,000		1,339,000,000		1,582,000,000	
Accrued liabilities		425,000,000		407,000,000		465,000,000
Other assets	-		-		-	
Current liabilities		2,763,000,000		3,080,000,000		2,370,000,000
Prepayments and accrued income		-		-		-
Non-current liabilities		4,808,000,000		3,812,000,000		4,498,000,000
Different income		-		-		-
Other liabilities		752,000,000		793,000,000		731,000,000
Total assets	17,083,000,000	17,083,000,000	17,557,000,000	17,557,000,000	16,691,000,000	16,691,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	18,000	17,494	16,218
Equity ratio	56.03%	61.13%	59.29%
Debt-equity ratio	78.47%	63.58%	68.66%

Others

	2023	2022	2021
Tax Expense Rate	16.81%	15.91%	10.53%

Income statement

	2023	2022	2021
Turnover	6,717,000,000	6,223,000,000	5,409,000,000
Net income	654,000,000	1,215,000,000	674,000,000
EBIT	893,864,700	1,549,160,700	877,482,300
Operating income before taxes	803,000,000	1,446,000,000	788,000,000
Cash Flow	1,419,000,000	1,039,000,000	1,220,000,000
Net interest income	-70,000,000	-67,000,000	-69,000,000
Research and development expenses	105,000,000	95,000,000	90,000,000
Income taxes	135,000,000	230,000,000	83,000,000
Result from investments in subsidiaries, associates and other	-13,000,000	2,000,000	-28,000,000
Revenues per employee	382,085	364,224	341,489

Board of Directors

Angelica Kohlmann	Member of the administrative board
Marion Helmes	Member of the administrative board
Olivier Verscheure	Member of the administrative board
Roger Nitsch	Member of the administrative board
Barbara Richmond	Member of the administrative board
Christoph Mäder	Member of the administrative board
Jürgen B. Steinemann	Member of the administrative board

Members of Management Board

Albert M. Baehny	Chairman of Managing Board
Christian Seufert	Member of Executive Committee
Daniel Palmacci	Member of Executive Committee
Gordon Bates	Member of Executive Committee
Jean-Christophe Hyvert	Member of Executive Committee
Maria Soler Nunez	Member of Executive Committee
Philippe Deecke	Member of Executive Committee
Ulrike Kaeppler	Member of Executive Committee